TY - JOUR T1 - [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer]. AU - Huang,C, AU - Bei,L, AU - Liu,T, PY - 2001/5/23/pubmed PY - 2001/6/22/medline PY - 2001/5/23/entrez SP - 285 EP - 8 JF - Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae JO - Zhongguo Yi Xue Ke Xue Yuan Xue Bao VL - 20 IS - 4 N2 - OBJECTIVE: CA50 and CA242 are newly recognized serum tumor marker. This study is to show their value in the diagnosis of digestive tract tumor. METHODS: 164 patients with malignant digestive disease and 69 patients with benign disease were chosen. CA50 and CA242 level of these patients were measured by immunoradiometric assay. RESULTS: The total sensitivity of CA50 and CA242 are 70% and 63% respectively. Two tumor markers rarely elevated in the patients with benign disease (false positive rate CA50 7.3%, CA242 4.3%). High percentage of elevated CA242 level was recorded in the patients with pancreatic and biliary cancers (Sensitivity 79%). Both have low sensitivity in patients with liver carcinoma. CONCLUSIONS: CA50 and CA242 are valuable marker in the diagnosis of digestive tract tumor. SN - 1000-503X UR - https://www.unboundmedicine.com/medline/citation/11367693/[The_clinical_value_of_tumor_marker_CA50_and_CA242_in_digestive_tract_cancer]_ L2 - https://medlineplus.gov/pancreaticcancer.html DB - PRIME DP - Unbound Medicine ER -